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Background: Several studies have been published favouring sigmoidectomy with primary anastomosis
over Hartmann’s procedure for perforated diverticulitis with purulent or faecal peritonitis (Hinchey grade
III or IV), but cost-related outcomes were rarely reported. The present study aimed to evaluate costs and
cost-effectiveness within the DIVA arm of the Ladies trial.
Methods: This was a cost-effectiveness analysis of the DIVA arm of the multicentre randomized
Ladies trial, comparing primary anastomosis over Hartmann’s procedure for Hinchey grade III or IV
diverticulitis. During 12-month follow-up, data on resource use, indirect costs (Short Form Health
and Labour Questionnaire) and quality of life (EuroQol Five Dimensions) were collected prospectively,
and analysed according to the modified intention-to-treat principle. Main outcomes were incremental
cost-effectiveness (ICER) and cost–utility (ICUR) ratios, expressed as the ratio of incremental costs and
the incremental probability of being stoma-free or incremental quality-adjusted life-years respectively.
Results: Overall, 130 patients were included, of whom 64 were allocated to primary anastomosis (46 and
18 with Hinchey III and IV disease respectively) and 66 to Hartmann’s procedure (46 and 20 respectively).
Overall mean costs per patient were lower for primary anastomosis (€20 544, 95 per cent c.i. 19 569
to 21 519) than Hartmann’s procedure (€28 670, 26 636 to 30 704), with a mean difference of €–8126
(–14 660 to –1592). The ICERwas €–39 094 (95 per cent bias-corrected and accelerated (BCa) c.i. –1213
to –116), indicating primary anastomosis to be more cost-effective. The ICUR was €–101 435 (BCa c.i.
–1 113 264 to 251 840).
Conclusion: Primary anastomosis is more cost-effective than Hartmann’s procedure for perforated
diverticulitis with purulent or faecal peritonitis.
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Introduction
Acute diverticulitis is a common diagnosis in developed
countries that is associated with considerable healthcare
costs1–5. The incidence of perforated diverticulitis with
purulent or faecal peritonitis (Hinchey grade III or IV) is
increasing, emphasizing the need for cost-effective emer-
gency surgical management6,7.
In recent years, results have been published favour-
ing sigmoidectomy with primary anastomosis (PA)
over Hartmann’s procedure (HP) for the treatment of
Hinchey III and IV diverticulitis8. Benefits of PA comprise
lower short-term morbidity rates after index and reversal
procedures, as well as a higher rate of stoma-free survival,
shorter time to stoma reversal and shorter postreversal
hospital stay8–11. Although these outcomes might reduce
associated costs, studies comparing the two treatment
strategies in terms of related costs and cost-effectiveness
are scarce. Therefore, a cost-effectiveness analysis was
undertaken comparing PA (with or without defunctioning
ileostomy) with HP in patients treated in the DIVA arm of
the Ladies trial11,12.
Methods
This cost-effectiveness analysis was conducted within
the DIVA arm of the Ladies trial. The study protocol,
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including details of cost analyses and clinical outcomes,
has been reported previously11,12. In summary, the Ladies
trial was an international, multicentre, parallel-group,
randomized, open-label superiority trial of the surgical
management of perforated diverticulitis. The aim of the
DIVA arm was to compare HP and PA (with or without
defunctioning ileostomy) as treatment for Hinchey III
or IV diverticulitis. After diagnostic laparoscopy, patients
were assigned randomly to HP or PA in a 1 : 1 ratio.
Patients with dementia, a history of sigmoidectomy
or pelvic radiotherapy, chronic steroid treatment (at least
20mg daily) or preoperative shock requiring inotropic sup-
port were excluded. The primary endpoint of the DIVA
arm was 12-month stoma-free survival and secondary
outcomes (such as morbidity and readmissions) were
also recorded. The study was registered at trialregister.nl
(NTR2037) and ClinicalTrials.gov (NCT01317485), and
designed in accordance with the Declaration of Helsinki
and good clinical practice guidelines. The study protocol
was approved by the ethical review board, and written
informed consent was obtained from all patients before
randomization. The CHEERS guidelines and checklist13
were used as guidance for the present cost-effectiveness
analysis.
Economic evaluation
The present analysis aimed to assess the cost-effectiveness
and cost–utility of HP compared with PA during the first
12months after the index procedure, and included both
direct and indirect costs (medical and non-medical). The
economic evaluation was performed from a societal per-
spective, and in accordance with the guidelines for health
economic analyses published by theDutchNationalHealth
Care Institute14.
Resource use
Data on resource use were collected prospectively through
clinical record forms and study questionnaires completed
1, 3, 6, 9 and 12months after the index procedure. Direct
medical costs were those related to index and stoma
reversal surgery and related admissions (such as ward
and ICU stay), reinterventions (acute relaparotomy or
percutaneous drainage), additional diagnostic imaging
(X-ray, ultrasound imaging, CT), readmissions, stoma
care, emergency department visits, and outpatient consul-
tation visits with the surgeon, gastroenterologist, general
practitioner or company physician. Costs of the index
procedure actually performed were used and did not
include the cost of the study protocol-based diagnostic
laparoscopy. Costs associated with home and informal care
and travel expenses were considered as direct non-medical
costs. Indirect non-medical costs resulting from work
absence or decreased productivity were determined by
use of the Short Form Health and Labour Question-
naire (SF-HLQ)15. To estimate loss of productivity, the
friction costs method was used with age-adjusted mean
daily wages derived from the Dutch National Health
Care Institute guideline14. Total costs per patient were
calculated by multiplying resources used by associated
unit costs.
Quality-adjusted life-years
Health-related quality of life (QoL) and quality-adjusted
life-years (QALYs) were derived from the EuroQol Five
Dimensions three-level questionnaire (EQ-5D-3L™;
EuroQol Group, Rotterdam, the Netherlands) at 2 and
4weeks, 3, 6 and 12months after the index procedure.
Outcomes were scored from 0 to 1 according to the
Dutch EQ-5D™ tariff, where 1 is considered to represent
optimal QoL.
Unit costs
Unit costs were calculated according to the methods
described by Vennix and colleagues16, and were estimated
based on top-down cost calculations from the hospital
costs ledger of the Amsterdam University Medical Cen-
tre and Dutch guideline on unit costing in healthcare17.
Moreover, bottom-up cost calculations for laparoscopic
and open sigmoidectomy with and without PA were
performed, including costs of instruments (reusable and
disposable), and costs of personnel and overheads per
time unit. As the index procedures and Hartmann’s rever-
sal procedures could be open or laparoscopic, mean
costs were calculated taking the ratio of these different
possible procedures into account. Costs were calcu-
lated in euros, adjusted to 2018 by the Dutch consumer
price index.
Statistical analysis
Depending on data distribution, continuous variables are
presented as median (i.q.r.) or mean(s.d.). Categorical
variables are shown as numbers with percentages. Patients
were analysed according to the modified intention-to-treat
principle, with costs calculated based on the index proce-
dure actually performed. The intention-to-treat approach
was deemed modified owing to the exclusion of three
patients shortly after randomization who were found
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to have alternative diagnoses11. The bias-corrected and
accelerated (BCa) bootstrapping method (1000 samples)
was used to calculate 95 per cent confidence intervals18.
Missing data on EQ-5D™ values and indirect costs
were imputed by means of multiple imputation, taking
into account age, sex, Hinchey grade, randomization
and direct costs. Imputed data were pooled according to
Rubin’s rule19.
To determine the robustness of the calculated costs,
sensitivity analyses were performed by varying unit costs
of resources used (direct medical costs). Incremental
cost-effectiveness (ICER) and cost–utility (ICUR) ratios
were calculated as the mean difference between treat-
ment groups in total costs per patient divided by the
mean difference in probability of being stoma-free and
mean difference in QALYs respectively. Cost-effectiveness
planes and acceptability curves were derived. Analyses
were performed using SPSS® version 24.0 (IBM, Armonk,
New York, USA) and R version 3.6.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Between 1 July 2010 and 22 February 2013, and between
9 June 2013 and 6 June 2016, patients could be included
in the DIVA arm of the Ladies trial. Trial inclusion was
temporarily paused, owing to the early termination of the
LOLA arm of the study. Eventually, a total of 130 patients
were included according to a modified intention-to-treat
principle, of whom 66 were analysed in the HP group
and 64 in the PA group. One patient in the PA group
was lost to follow-up after 30 days (Fig. S1, supporting
information). All patients were included in the present
cost evaluation. Baseline and operative characteristics are
summarized in Table 1. Full trial details and outcomes
have been published previously11. Response rates to the
SF-HLQ questionnaires are documented in Table S1
(supporting information).
Costs and resource use
A summary of unit costs of major resources is provided
in Table 2, with full details in Table S2 (supporting infor-
mation). Resource use and calculated costs are shown in
Table 3. Stoma-related costs were significantly higher in
the HP group (€8372, 95 per cent c.i. 7316 to 9429) than
in the PA group (€4382, 3481 to 5284), with a mean dif-
ference of €–3990 (–5370 to –2611). Overall total costs
were €1 892 206 for the HP group and €1 314 798 for the
PA group. Mean costs per patient were €28 670 (26 636 to
30 704) and €20 544 (19 569 to 21 519) respectively. This
Table 1 Summary of baseline and operative characteristics
Hartmann’s
procedure
Primary
anastomosis
(n = 66) (n = 64)
Patient characteristics
Age (years)* 61⋅7(11⋅4) 62⋅4(13⋅1)
Sex ratio (F :M) 25 : 41 23 : 41
BMI (kg/m2)* 28⋅0(4⋅7) 26⋅3(4⋅8)
ASA fitness grade
I–II 37 (63) 45 (76)
III–IV 22 (37) 14 (24)
Missing 7 5
Hinchey grade IV 20 (30) 18 (28)
Operative characteristics
Laparoscopic lavage 0 1 (2)
Hartmann’s procedure 65 (98) 7 (11)
Primary anastomosis 1 (2) 56 (88)
Stoma
No 1 (2) 18 (28)
Yes 65 (98) 46 (72)
Duration of surgery (min)† 118 (96–135) 125 (110–154)
Laparoscopic procedure 20 (30) 17 (27)
Values in parentheses are percentages unless indicated otherwise; values are
*mean(s.d.) and †median (i.q.r.).
Table 2 Major resources and unit costs
Mean cost (€) Unit
Hartmann’s procedure 3247 Procedure
Primary anastomosis 3914 Procedure
Laparoscopic lavage 2346 Procedure
Ileostomy reversal 2655 Procedure
Colostomy reversal 4087 Procedure
Acute relaparotomy 3476 Procedure
Percutaneous drainage 14 Procedure
Elective sigmoid resection 4266 Procedure
Incisional hernia repair 1305 Procedure
Surgical ward stay 419 Day
ICU stay 2084 Day
Values are indexed for 2018.
amounted to amean difference in costs of €–8126 (–14 660
to –1592) in favour of PA.
Cost-effectiveness and cost–utility
The mean probability of being stoma-free at end of the
12-month follow-up was 86 (95 per cent c.i. 74 to 93)
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Table 3 Resource use and costs
Hartmann’s procedure (n = 66) Primary anastomosis (n = 64)
Unit Total units Total costs (€) Total units Total costs (€)
Index admission
Hartmann’s procedure Procedure 65 211 083 7 22732
Primary anastomosis Procedure 1 3914 56 219181
Laparoscopic lavage Procedure 0 0 1 2346
Surgical ward Day 733 307076 591 247588
Intensive care unit Day 197 410611 87 181336
Additional imaging Test 264 31 039 159 21448
Subtotal 963 723 694630
Mean subtotal per patient 14 602 (8514, 20 689) 10 854 (9126 to 12 581)
Mean difference in subtotal –3748 (–10 101, 2604)
Readmissions and reinterventions
Acute reinterventions Procedure 18 31 064 12 28154
Elective reinterventions Procedure 4 5218 1 1305
Readmission to surgical ward Day 172 72056 142 59488
Readmission intensive care unit Day 0 0 0 0
Subtotal 108 339 88 946
Mean subtotal per patient 1641 (626, 2657) 1390 (677, 2102)
Mean difference in subtotal –252 (–1488 to 984)
Stoma-related costs
Stoma care Day 13118 245965 8288 104737
Reversal surgery Procedure 45 183 915 38 106612
Reversal admission (surgical ward + ICU) Day 277 122705 165 69123
Subtotal 552 584 280473
Mean subtotal per patient 8372 (7316, 9429) 4382 (3481, 5284)
Mean difference in subtotal –3990 (–5370, –2611)
Other costs
Ìmaging Test 64 9282 38 4811
Consultations and travel expenses Visit 349 30 038 295 26423
Total direct medical costs 1663966 1095283
Indirect non-medical costs 228240 219515
Total costs (12months) 1892206 1314798
Mean cost per patient 28670 (26 636, 30 704) 20 544 (19 569, 21 519)
Mean difference in costs –8126 (–14 660, –1592)
Values in parentheses are 95 per cent confidence intervals. Mean costs are shown, indexed for 2018. Smaller cost groups (such as hospital and general
practitioner visits) are included in (sub)total costs.
per cent for the PA group and 65 (53 to 75) for the
HP group, with a significant mean difference of 21 (7
to 36) per cent. Fig. 1 shows a cost-effectiveness plane,
indicating the relationship between incremental costs and
the incremental probability of being stoma-free and alive.
The ICER was €–39 094 (95 per cent BCa c.i. –1213 to
–116), indicating that PA was more cost-effective than HP.
The associated willingness-to-pay curve is shown in Fig. S2
(supporting information).
The mean value of QALYs during the 12-month
follow-up was 0⋅72 (95 per cent c.i. 0⋅69 to 0⋅76) in
the PA group, compared with 0⋅64 (0⋅60 to 0⋅68) in the
HP group. The mean difference in QALYs was 0⋅08
(–0⋅03 to 0⋅19), which was not statistically significant. The
ICUR was €–101 435 (95 per cent BCa c.i. –1 113 264 to
251 840). A cost–utility plane and willingness-to-pay curve
are shown in Fig. 2 and Fig. S3 (supporting information)
respectively.
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Fig. 1 Cost-effectiveness plane
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Table 4 Sensitivity analyses of medical costs
Hartmann’s procedure (€) Primary anastomosis (€) Cost difference (€)
Total medical costs (base-case analysis) 25212 (21 251, 34 132) 17 114 (15 297, 19 636) –8098 (–17 016, –3550)
Index surgery
–50% 23583 (19 603, 32 482) 15 206 (13 398, 17 789) –8377 (–17 214, –3818)
+50% 26840 (22 847, 37 381) 19 022 (16 978, 21 455) –7818 (–18 129, –3269)
Hospital stay (ward, ICU)
–20% 23036 (19 258, 30 896) 15 773 (14 139, 17 939) –7263 (–14 878, –2910)
+20% 27386 (22 398, 39 156) 18 454 (16 284, 21 358) –8932 (–19 534, –3261)
Stoma–associated costs
–20% 23537 (19 566, 33 672) 16 237 (14 598, 18 812) –7300 (–16 843, –2507)
+20% 26886 (22 880, 35 540) 17 990 (16 064, 20 586) –8896 (–17 734, –4320)
Acute or elective reintervention
–20% 25102 (21 174, 35 659) 17 022 (15 370, 19 443) –8079 (–18 375, –3742)
+20% 25321 (21 399, 36 105) 17 206 (15 499, 19 746) –8116 (–18 526, –3742)
Values in parentheses are 95 per cent confidence intervals.
Sensitivity analyses
Table 4 shows the results of sensitivity analyses, in which
unit costs for specified cost groups were increased
and decreased by 20 or 50 per cent, while those for
other cost groups were not changed. Overall, these
results demonstrated that PA was associated with
lower costs, with cost differences ranging from €–7263
to €–8932.
Discussion
Admission rates for diverticulitis have increased over the
past few decades6,20–23 and the incidence of perforated dis-
ease, for which surgery is often needed, has risen24–26. In
a retrospective study27, overall expenses were between 74
and 229 per cent higher for HP than PA. More recently28,
in-hospital costs within an RCT were found to be higher
forHP, but this was not statistically significant. The present
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Fig. 2 Cost–utility plane
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study differed from previous analyses by capturing all costs
prospectively, including indirect non-medical and other
resource expenses (such as those related to readmissions
or outpatient department visits) over the full 12-month
follow-up. It showed that PA was more cost-effective in
the first postoperative year and in terms of the proba-
bility of being stoma-free. Advantages of PA derive from
a shorter time to, and less morbidity after, stoma rever-
sal, and a shorter hospital stay, which are likely to reduce
costs11. Indeed, a large difference in absolute stoma-related
costs was identified in favour of PA. This is in line with a
cost-effectiveness analysis of the LOLA arm of the Ladies
trial16, in which stoma-related costs were higher for resec-
tion than laparoscopic lavage for Hinchey III diverticulitis,
and the economic analysis of the related DILALA (DIver-
ticulitis – LAparoscopic LAvage versus resection (Hart-
mann’s procedure) for acute diverticulitis with peritonitis)
study29.
In terms of generalizability, some aspects are of impor-
tance to consider when interpreting the present outcomes.
The majority of patients included in the Ladies trial
were Dutch11, and unit costs and subsequent calculations
are based on that healthcare system. The results should
be interpreted within the context of the inclusion and
exclusion criteria that applied to the DIVA arm. There-
fore, strictly speaking, the present outcomes apply only
to haemodynamically stable, immunocompetent patients
aged less than 85 years11. Enrolment was terminated
early because of slow accrual. Although not uncommon
for RCTs in the emergency setting30, early termination
may limit the sample size and statistical power. The
study was not specifically powered to show differences in
cost-associated or patient-reported outcomes. Hence, it
was decided not to differentiate between Hinchey III and
IV diverticulitis in the present study, as this would have
further reduced group sizes. In spite of the sample size,
significant differences in overall mean costs per patient
were identified, and their robustness was demonstrated in
sensitivity analyses. Another limitation was the response
rate to the questionnaires sent out during follow-up, which
ranged from 47 to 64 per cent. Multiple imputation tech-
niques were used to handle missing data and to decrease
the influence of potential attrition bias.
This study has several strengths, including the setting
of a multicentre randomized trial with cost data collected
prospectively from a societal perspective, and indirect
non-medical costs (such as absence from work and pro-
ductivity losses) taken into account. These factors are
relevant to consider as the disease is increasingly being
seen in younger patients of working age20,21,23. The assess-
ment of unit costs came from the hospital ledger and
Dutch costing manual14, rather than being derived from
diagnosis-related group data, to better reflect clinical
practice at a more individual level.
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In general, the treatment of diverticulitis has shifted
towards less aggressive approaches, which might also have
beneficial effects on associated costs31. The avoidance of
antibiotics for uncomplicated diverticulitis has been proven
to be safe in both the short and long term32–35. The role
of percutaneous drainage for diverticulitis with abscess
formation has been debated36,37. Subsequently, follow-up
without elective colectomy after non-operative treatment
of an initial episode of diverticulitis with abscess formation
or local extraluminal air seems justified38,39. Moreover,
evidence shows that HP for perforated diverticulitis should
be avoided if possible and that PA is preferred9–11. The
present cost-effectiveness analysis has provided a health
economic argument for use of PA over HP for perforated
diverticulitis.
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